Bronfman E.L. Rothschild L.P. lessened its holdings in C.R. Bard, Inc. (NYSE:BCR) by 43.3% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 447 shares of the medical instruments supplier’s stock after selling 341 shares during the period. Bronfman E.L. Rothschild L.P.’s holdings in C.R. Bard were worth $141,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently made changes to their positions in BCR. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its stake in C.R. Bard by 70.4% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 460 shares of the medical instruments supplier’s stock valued at $145,000 after purchasing an additional 190 shares during the period. ClariVest Asset Management LLC acquired a new position in C.R. Bard in the first quarter valued at $148,000. SRS Capital Advisors Inc. increased its stake in C.R. Bard by 0.7% in the first quarter. SRS Capital Advisors Inc. now owns 598 shares of the medical instruments supplier’s stock valued at $148,000 after purchasing an additional 4 shares during the period. Parallel Advisors LLC boosted its holdings in shares of C.R. Bard by 283.8% in the first quarter. Parallel Advisors LLC now owns 499 shares of the medical instruments supplier’s stock valued at $153,000 after acquiring an additional 369 shares in the last quarter. Finally, Penserra Capital Management LLC boosted its holdings in shares of C.R. Bard by 9.5% in the first quarter. Penserra Capital Management LLC now owns 828 shares of the medical instruments supplier’s stock valued at $205,000 after acquiring an additional 72 shares in the last quarter. Institutional investors and hedge funds own 79.34% of the company’s stock.
Shares of C.R. Bard, Inc. (BCR) traded down 0.21% during mid-day trading on Friday, hitting $319.85. 134,475 shares of the company’s stock were exchanged. The firm has a 50 day moving average price of $320.21 and a 200-day moving average price of $296.89. The company has a market capitalization of $23.24 billion, a price-to-earnings ratio of 41.99 and a beta of 0.60. C.R. Bard, Inc. has a 52 week low of $203.63 and a 52 week high of $324.58.
C.R. Bard (NYSE:BCR) last issued its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $2.92 EPS for the quarter, beating analysts’ consensus estimates of $2.84 by $0.08. C.R. Bard had a return on equity of 48.70% and a net margin of 14.99%. The firm had revenue of $979.70 million for the quarter, compared to analyst estimates of $976.53 million. During the same period in the prior year, the firm posted $2.54 EPS. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. On average, equities analysts anticipate that C.R. Bard, Inc. will post $11.84 EPS for the current year.
WARNING: “Bronfman E.L. Rothschild L.P. Has $141,000 Position in C.R. Bard, Inc. (NYSE:BCR)” was first reported by BBNS and is owned by of BBNS. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://baseballnewssource.com/markets/c-r-bard-inc-bcr-shares-sold-by-bronfman-e-l-rothschild-l-p/1601736.html.
In other C.R. Bard news, insider John P. Groetelaars sold 23,687 shares of the company’s stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $318.73, for a total value of $7,549,757.51. Following the transaction, the insider now directly owns 31,445 shares of the company’s stock, valued at approximately $10,022,464.85. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.80% of the company’s stock.
Several brokerages have recently weighed in on BCR. Jefferies Group LLC reaffirmed a “hold” rating and issued a $317.00 target price on shares of C.R. Bard in a report on Thursday. BidaskClub cut shares of C.R. Bard from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Zacks Investment Research cut shares of C.R. Bard from a “buy” rating to a “hold” rating in a research report on Tuesday, June 20th. Finally, BMO Capital Markets reissued a “hold” rating and issued a $317.00 price objective on shares of C.R. Bard in a research report on Tuesday, July 11th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. C.R. Bard presently has a consensus rating of “Hold” and an average price target of $285.67.
About C.R. Bard
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with our FREE daily email newsletter.